• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Oncoimmunology >The effect of concomitant use of statins NSAIDs low-dose aspirin metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
【2h】

The effect of concomitant use of statins NSAIDs low-dose aspirin metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis

机译：伴随使用他汀类药物NSAIDS低剂量阿司匹林二甲双胍和β-阻滞剂对接受免疫检查点抑制剂的患者的结果的影响：系统审查和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immunotherapy shows promising therapeutic efficacy against various types of cancer, but most fail to respond. Preclinical studies have suggested that concomitant medications, such as statins, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, metformin and beta-blockers, might affect clinical outcomes if used with immune checkpoint inhibitors (ICIs), but their clinical roles are conflicting. This meta-analysis investigates the effect of these concomitant medications on outcomes in patients treated with ICIs. A search was conducted for all reports published until 31 March 2021 in PubMed, Web of Science, Cochrane Library, EMBASE and conference proceedings. Studies were included if they investigated the association between the concomitant use of these medications and progression-free survival (PFS) or overall survival (OS) during ICI treatment. A total of 3331 patients from 13 eligible studies were included. Among them, five articles on statins, six studies evaluating NSAIDs, five studies employing low-dose aspirin, eight studies on metformin and four articles on beta-blockers were included. The concomitant use of statins during ICI treatment was correlated with improved OS and PFS. Low-dose aspirin was associated with better PFS instead of OS. No significant association was demonstrated between the concurrent use of NSAIDs, beta-blockers and metformin and OS or PFS. The concomitant use of statins and low-dose aspirin during ICI treatment showed a positive impact on treatment outcomes. The concurrent use of NSAIDs, beta-blockers and metformin is not significantly associated with clinical benefits. The effect of these medications in different cancer patients treated with ICI is needed to be further validated.
机译：免疫疗法显示对各种类型的癌症有前途的治疗疗效，但最不能回应。临床前研究表明，如果与免疫检查点抑制剂（ICIS）一起使用，伴随的药物，例如他汀类药物，非甾体抗炎药（NSAIDs），阿司匹林，二甲双胍和β-阻滞剂可能会影响临床结果，但它们的临床角色是冲突。该荟萃分析研究了这些伴随药物对用ICIS治疗患者的结果的影响。在PubMed，Cochrane图书馆，Embase和会议诉讼中，为2021年3月31日发布的所有报告进行了搜索。如果他们在ICI治疗期间调查了伴随这些药物和无进展生存（PFS）或整体存活（OS）之间的关联，则包括研究。共有来自13项合格研究的3331名患者。其中，在他汀类药物的五篇文章中，评估NSAID的五项研究，五项研究采用低剂量阿司匹林，八项研究二甲双胍和四种物品的β-窝体。在ICI处理期间伴随他汀类药物与改善的OS和PFS相关。低剂量阿司匹林与更好的PFS而不是OS相关联。在NSAIDS，Beta阻滞剂和二甲双胍和OS或PFS的同时使用之间证明了没有显着的关联。在ICI治疗期间伴随他汀类药物和低剂量阿司匹林对治疗结果产生了阳性影响。 NSAIDS，Beta阻滞剂和二甲双胍的同时使用与临床益处没有显着相关。需要进一步验证这些药物对不同癌症患者的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号